News

A case of cold agglutinin disease (CAD) secondary to a type of blood cancer called B-cell lymphoma was confirmed after carefully examining blood samples under the microscope, a study reports. The case study illustrates the “importance of microscopic observation in the exploration of undergoing causes of cold agglutination,” the researchers…

A man had stroke-like symptoms, a heart attack, and rotting skin that were determined to be likely caused by cold agglutinin disease (CAD). While similar issues have been reported with CAD, this may be the first report of these symptoms occurring at the same time in one patient, the…

For a toddler in Brazil, cold agglutinin disease (CAD) occurred secondary to an infection with an adenovirus, a common virus that can cause symptoms similar to a cold or the flu, a case study reports. According to the researchers, this represents “the first pediatric case of cold agglutinin syndrome…

A case of cold agglutinin disease (CAD), found to be secondary to a type of blood cancer called B-cell lymphoma, successfully resolved after the cancer was appropriately treated, a study shows. The case report illustrates the importance of identifying the underlying cause of CAD so treatment can be given,…

Long-term treatment with Enjaymo (sutimlimab-jome) led to sustained improvements in life quality and reductions in fatigue for people with cold agglutinin disease (CAD), according to 2.5 years of data from the Phase 3 CARDINAL clinical trial. “[Enjaymo] provides sustained and durable treatment benefits in chronic CAD, including a…

Two approved blood cancer treatments, daratumumab and bortezomib, were each partially effective at reducing signs of cold agglutin disease (CAD) in two people with hard-to-treat cases of the autoimmune disorder, a study showed. These two therapies, alone or in combination, also were found to effectively treat five of six people with other…

Legionnaires’ disease — a lung infection caused by a group of bacteria called Legionella — caused secondary cold agglutinin disease (CAD) in a 40-year-old man, a case study reports. The case, which represents the second reported case of CAD secondary to Legionnaires’ disease, suggest doctors should consider this infection…

Sanofi’s experimental therapy SAR445088 effectively blocks the classic complement pathway — a part of the immune system that’s implicated in cold agglutinin disease (CAD) — and reduced red blood cell destruction in a cellular model of CAD, a study showed. SAR445088’s more targeted action may make it a…

A woman with a mixed form of autoimmune hemolytic anemia (AIHA), who was having only temporary responses to standard treatment, experienced complete disease remission after being given an interleukin-23 (IL-23) inhibitor for a separate condition, a case study shows. IL-23 inhibitor therapies are used for other inflammatory diseases, but have…

Specially designed miniaturized antibodies, or nanobodies, reduced blood cell destruction in a new mouse model of a disease similar to cold agglutinin disease (CAD), a study showed. These findings suggest that the nanobodies, designed to suppress the complement cascade by blocking the complement component 2 (C2) protein, could…